Cargando…

Tirapazamine-cisplatin: the synergy.

Tirapazamine is a novel bioreductive agent with selective cytotoxicity against hypoxic tumour cells. Synergy with cisplatin and other chemotherapeutic agents has been shown in preclinical trials. Pharmacokinetic studies of tirapazamine have revealed that exposure increases with dose over the range o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatzemeier, U., Rodriguez, G., Treat, J., Miller, V., von Roemeling, R., Viallet, J., Rey, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149886/ https://www.ncbi.nlm.nih.gov/pubmed/9647615

Ejemplares similares

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Electronic structure and reactivity of tirapazamine as a radiosensitizer
por: Romero, José, et al.
Publicado: (2021)

Applicability of Combination with Tirapazamine in Boron Neutron Capture Therapy
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1998)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity
por: Guise, Chris P., et al.
Publicado: (2020)

Development and Validation of a Kilogram-Scale Synthesis of Tirapazamine
por: Lienard, Philippe, et al.
Publicado: (2020)

Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2019)

Changes in the Sensitivity of Intratumor Cells during Fractionated Tirapazamine Administration
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

Ring-Selective Fragmentation in the Tirapazamine Molecule upon Low-Energy Electron Attachment
por: Arthur-Baidoo, Eugene, et al.
Publicado: (2021)

Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
por: Ajnai, Giimel, et al.
Publicado: (2022)

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
por: Lartigau, E., et al.
Publicado: (1996)

Tirapazamine-Doxorubicin Interaction Referring to Heart Oxidative Stress and Ca(2+) Balance Protein Levels
por: Sliwinska, Justyna, et al.
Publicado: (2012)

The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ
por: Yehl, Matthew, et al.
Publicado: (2023)

Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
por: Siim, B. G., et al.
Publicado: (1996)

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
por: Khan, S., et al.
Publicado: (1995)

Reactions in Tirapazamine Induced by the Attachment of Low‐Energy Electrons: Dissociation Versus Roaming of OH
por: Arthur‐Baidoo, Eugene, et al.
Publicado: (2020)

Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
por: Abi-Jaoudeh, Nadine, et al.
Publicado: (2021)

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
por: Patterson, A. V., et al.
Publicado: (1997)

Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy
por: Chen, Hongfang, et al.
Publicado: (2021)

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
por: Chinje, E C, et al.
Publicado: (1999)

Does Doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?
por: Sagar, Jayesh, et al.
Publicado: (2009)

Tirapazamine-loaded CalliSpheres microspheres: Preparation and characterization as a chemoembolization agent for liver cancer
por: Zhang, Xin, et al.
Publicado: (2023)

Effects of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1997)

Synergy, Additivity, and Antagonism between Cisplatin and Selected Coumarins in Human Melanoma Cells
por: Wróblewska-Łuczka, Paula, et al.
Publicado: (2021)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

Comparison of in vivo Efficacy of Hypoxic Cytotoxin Tirapazamine and Hypoxic Cell Radiosensitizer KU‐2285 in Combination with Single and Fractionated Irradiation
por: Shibata, Toru, et al.
Publicado: (1996)

Effect of Tirapazamine, Metformin or Mild Hyperthermia on Recovery From Radiation-Induced Damage in Pimonidazole-Unlabeled Quiescent Tumor Cells
por: Masunaga, Shin-ichiro, et al.
Publicado: (2017)

Usefulness of Tirapazamine as a Combined Agent in Chemoradiation and Thermo‐chemoradiation Therapy at Mild Temperatures: Reference to the Effect on Intratumor Quiescent Cells
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

The synergistic radiosensitizing effect of tirapazamine-conjugated gold nanoparticles on human hepatoma HepG2 cells under X-ray irradiation
por: Liu, Xi, et al.
Publicado: (2016)

Introduction
por: Gatzemeier, U
Publicado: (2003)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

Auranofin induces urothelial carcinoma cell death via reactive oxygen species production and synergy with cisplatin
por: Chen, San-Yuan, et al.
Publicado: (2022)

Interpersonal Synergies
por: Riley, Michael A., et al.
Publicado: (2011)

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qrkl2vgkmd8u5gor7uh1fnckd9